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ceptor, haemochromatosis (HFE) protein and DMT1 
(NRAMP2/DCT1). In literature, alterations in the trans-
ferrin receptor gene have been associated with HFE  [5] , 
and  HFE gene mutations are associated with a reduction 
in the amount of rhEPO necessary to support erythro-
poiesis in haemodialysis patients  [6] . However, these 2 
proteins are unlikely to be the main causes of the resis-
tance to rhEPO therapy in CKD patients under haemo-
dialysis, as HFE is characterized by increases in serum 
iron parameters, namely transferrin saturation, not 
found in non-responder CKD patients. On the other 
hand, the  DMT1 gene could be a good candidate to un-
derlie the variability of response to rhEPO in CKD pa-
tients. Indeed, the few described mutation cases in the 
 DMT1 gene are associated with an inhibition of intesti-
nal iron absorption and a decrease in erythroid cell pre-
cursor iron uptake, resulting in hypochromic and mi-
crocytic anaemia  [7] . This type of anaemia is similar to 
that observed in non-responder CKD patients, resulting 
of a functional iron-depleted erythropoiesis in the pres-
ence of adequate serum iron levels  [4] . As far as we know, 
there are no data regarding the association of  DMT1 gene 
 The management of anaemia in chronic kidney dis-
ease (CKD) was changed by the introduction of recombi-
nant human erythropoietin (rhEPO) therapy, allowing a 
significant correction of anaemia; however, around 5–
10% of the patients show a marked resistance to rhEPO 
therapy  [1, 2] . Several conditions were reported as being 
associated with rhEPO resistance, but changes in iron ho-
meostasis is one of the most studied causes  [3] .
 CKD patients who do not respond to rhEPO therapy 
seem to present a ‘functional’ iron deficiency, character-
ized by the presence of adequate iron stores as defined by 
conventional criteria, but apparently with an inability to 
sufficiently mobilize this iron to adequately support 
erythropoiesis  [4] . We recently found that compared with 
responder patients, non-responders presented no statisti-
cal differences for iron, transferrin saturation and ferri-
tin values, but had a significantly lower haemoglobin 
concentration and mean cell haemoglobin, as well as sig-
nificantly higher plasma levels of the soluble transferrin 
receptor (s-TfR)  [4] .
 Iron uptake from plasma to erythroid precursor cells 
is regulated by different proteins, namely transferrin re-
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mutations/polymorphisms in patients with ‘functional’ 
iron deficiency.
 In this context, we studied 63 CKD patients under 
haemodialysis (36 males, 27 females; age 62.1  8 15.7 
years) and rhEPO treatment (10 with darbopoietin-  and 
53 with epoetin), including 32 responders and 31 non-re-
sponders to rhEPO therapy  [8] . The rhEPO maintenance 
dose for responders was 89.65  8 57.62 U/kg/week and for 
non-responders 572.99  8 193.84 U/kg/week. Patients 
with autoimmune disease, malignancy, haematological 
disorders and acute or chronic infection were excluded. 
Intravenous iron supplementation (iron sucrose) was 
based on the European Best Practice Guidelines for the 
Management of Anemia in CKD patients under haemo-
dialysis  [8] . No statistically significant difference was 
found in total iron supplement given during the last year, 
between responder and non-responder patients. We also 
studied a control group with 26 healthy volunteers, pre-
senting normal haematological and biochemical values, 
with no history of renal or inflammatory diseases, and, 
as far as possible, age and gender matched with the CKD 
patients (8 males, 17 females; mean age 47.81  8 14.69). 
All patients and controls gave their informed consent to 
participate in this study.
 In all participants (patients and controls), haemato-
logical counts were performed (Sysmex K1000; Sysmex, 
Hamburg, Germany) as well as the evaluation of serum 
iron levels (Randox Laboratories Ltd., UK), ferritin (Ran-
dox Laboratories Ltd.) and transferrin (Randox Labora-
tories Ltd.) and of plasma s-TfR (human sTfR immunoas-
say, R&D Systems, Minneapolis, Minn., USA). Genotype 
of the c.309+44C ] A, c.1254T ] C, c.1303T ] C and 
c.1629–16C ] G  DMT1 polymorphisms/mutations was 
performed by restriction fragment length analysis, using 
the conditions previously described  [9] , with minor mod-
ifications. Mutation nomenclature was used according to 
the recommendations of the Human Genome Variation 
Society (2005; http://www.hgvs.org/mutnomen).
 The frequencies of the  DMT1 gene polymorphisms/
mutations tested are shown in  table 1 . No statistically sig-
nificant differences were found in allele frequency be-
tween the controls and CKD patients, nor when compar-
ing the 2 groups of patients. These frequencies were sim-
ilar to those previously described in literature  [9] .
 Estimations of the haplotype frequencies were per-
formed using the program Arlequin version 3.11  [10] . 
This program estimates the maximum likelihood haplo-
type frequencies from observed data using an expecta-
tion-maximization algorithm for multilocus genotype 
data when the genetic phase is unknown. The most fre-
quent haplotypes found were: CCTC (c.309+44C, 
c.1254C, c.1303T, c.1629–16C), ACCC (c.309+44A, 
c.1254C, c.1303C, c.1629–16C) and ACTG (c.309+44A, 
c.1254C, c.1303T, c.1629–16G) ( table 2 ). No statistically 
significant differences were found in the frequencies of 
the CCTC and ACCC haplotypes between controls and 
CKD patients, nor between responders and non-respond-
er patients. The frequencies of these 2 haplotypes are very 
similar to those found in other populations  [9] . However, 
the ACTG haplotype was statistically more frequent in 
CKD patients than in the control group (p  !  0.05); nev-
ertheless, no statistical differences were found between 
 Table 1. Frequency of studied DMT1 alleles in CKD patients and controls (%)
 c.309+44C ] A  c.1254T ] C  c.1303T ] C  c.1629–16C ] G 
C allele A allele T allele C allele T allele C allele C allele G allele
 CKD patients (n = 63)  76.98  23.02  84.13  15.87 99.21  0.79  92.06  7.94 
 rhEPO responders (n = 32)  73.44  26.56  82.81  17.19  100  0  92.19  7.81 
 rhEPO non-responders (n = 31)  80.65  19.35  85.48  14.52 98.39  1.61  91.94  8.06 
 Controls (n = 26)  76.92  23.08  80.77  19.23  100  0  94.23  5.77 
 Table 2. Haplotype frequencies in CKD patients and controls de-
termined by Arlequin version 3.11 (%)
 CCTC  ACCC  ACTG 
 CKD patients (n = 63)  65.87  18.25  6.35 
 rhEPO responders (n = 32)  64.06  21.88  7.81 
 rhEPO non-responders (n = 31)  67.74  14.51  4.83 
 Controls (n = 26)  71.15 5.76  0 
 CCTC: c.309+44C; c.1254C; c.1303T; c.1629–16C.
 ACCC: c.309+44A; c.1254C; c.1303C; c.1629–16C.
 ACTG: c.309+44A; c.1254C; c.1303T; c.1629–16G. 
responder and non-responder CKD patients. The fre-
quency of this ACTG haplotype in CKD patients was also 
very similar to that found in literature; however, in the 
control group, the prevalence of this haplotype is signifi-
cantly lower than that found in other previously described 
control populations  [9] . These differences can result from 
the small sample size of our control group.
 When we compared rhEPO doses, haematological 
data and iron status (iron, ferritin and transferrin satura-
tion) of CKD patients under haemodialysis by haplotype, 
no statistically significant differences were found (data 
not shown), suggesting that  DMT1 gene haplotypes are 
not associated with changes in haematological data and 
iron status in CKD patients, nor in rhEPO doses required 
to achieve target haemoglobin levels.
 CKD patients under haemodialysis are treated with 
intravenous iron; thus, the main factors limiting iron 
availability for erythropoiesis could be a deficiency in 
iron uptake to erythroblast and/or iron trapping into 
macrophages. The latter is associated with a failure in re-
cycling/export mainly due to a decreased activity of the 
iron export ferroportin-1 (related to increased hepcidin 
expression associated with the inflammatory process 
found in haemodialysis patients). As DMT1 protein is re-
lated to both mechanisms, it is reasonable to hypothesize 
that mutations/polymorphisms in this gene may decrease 
the iron availability for erythroblast iron metabolism and 
haem biosynthesis in CKD non-responder patients to 
rhEPO therapy, even in the presence of adequate serum 
iron levels. However, our study failed to demonstrate a 
link between mutations/polymorphisms in the  DMT1 
gene and resistance to rhEPO therapy. Moreover, no 
 influence of  DMT1 gene mutations/polymorphisms on 
rhEPO doses, haematological data and iron status was 
demonstrated in our CKD patients under haemodialysis. 
Further studies are warranted, namely using a higher 
number of CKD patients, full screening of mutations in 
 DMT1 gene and/or other genes related to iron metabo-
lism, to clarify the mechanism underlying rhEPO resis-
tance.
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